

- 36 -

**We Claim:**

1. A method for treating a mammal suffering from a myocardial infarction comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a chemical Src family tyrosine kinase inhibitor.

2. The method of claim 1 wherein the mammal is a human.

3. The method of claim 1 wherein the mammal is a non-human mammal.

4. The method of claim 1 wherein the Src family tyrosine kinase inhibitor is a an inhibitor of Src protein.

5. The method of claim 4 wherein the chemical inhibitor is selected from the group consisting of a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-*d*]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof.

6. The method of claim 5 wherein the pyrazolopyrimidine class Src family tyrosine kinase inhibitor is a member of the group consisting of 4-amino-5-(4-methylphenyl)-7-(*t*-butyl)pyrazolo[3,4-*d*] pyrimidine, 4-amino-5-(4-chlorophenyl)-7-(*t*-butyl) pyrazolo[3,4-*d*]pyrimidine, and a mixture thereof.

7. The method of claim 5 wherein the macrocyclic dienone class Src family tyrosine kinase inhibitor is a member of the group consisting of Geldanamycin, Herbimycin A, Radicicol R2146, and a mixture thereof.

8. The method of claim 5 wherein the pyrido[2,3-*d*]pyrimidine class Src family tyrosine kinase inhibitor is PD173955.

- 37 -

9. The method of claim 5 wherein the 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor is SKI-606.

10. The method of claim 1 wherein the pharmaceutical composition is administered to the mammal by intraperitoneal injection.

5 11. The method of claim 1 wherein the pharmaceutical composition is administered to the mammal by intravenous injection.

12. The method of claim 1 wherein the pharmaceutical composition is administered to the mammal within about 6 hours after the myocardial infarction.

10 13. The method of claim 1 wherein the pharmaceutical composition is administered to the mammal within about 24 hours after the myocardial infarction.

14. An article of manufacture comprising packaging material and a pharmaceutical composition contained within the packaging material, wherein the pharmaceutical composition is present in an amount capable of reducing necrosis in coronary tissue suffering from an impeded blood supply, the packaging material comprising a label which indicates that said pharmaceutical composition can be used for treatment of myocardial infarction, and wherein the pharmaceutical composition comprises a chemical Src family tyrosine kinase inhibitor and a pharmaceutically acceptable carrier therefor.

15 16. The article of manufacture of claim 14 wherein the Src family tyrosine kinase inhibitor is an inhibitor of Src protein.

17. The article of manufacture of claim 15 wherein the chemical inhibitor is selected from the group consisting of a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-*d*]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof.

- 38 -

17. The article of manufacture of claim 16 wherein the pyrazolopyrimidine class Src family tyrosine kinase inhibitor is selected from the group consisting of 4-amino-5-(4-methylphenyl)-7-(*t*-butyl)pyrazolo[3,4-*d*]pyrimidine, 4-amino-5-(4-chlorophenyl)-7-(*t*-butyl)pyrazolo[3,4-*d*]pyrimidine, and a mixture thereof.

18. The article of manufacture of claim 15 wherein the macrocyclic dienone class Src family tyrosine kinase inhibitor is selected from the group consisting of Geldanamycin, Herbimycin A, Radicicol R2146, and a mixture thereof.

19. The article of manufacture of claim 15 wherein the pyrido[2,3-*d*]pyrimidine class Src family tyrosine kinase inhibitor is PD173955.

20. The article of manufacture of claim 15 wherein the 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor is SKI-606.

21. A method for prophylactic treatment of a mammal at risk of myocardial infarction, the method comprising administering to the mammal a prophylactic amount of a pharmaceutical composition comprising a chemical Src family tyrosine kinase inhibitor.

22. The method of claim 21 wherein the mammal is a non-human mammal.

23. The method of claim 21 wherein the mammal is a human.

24. The method of claim 21 wherein the pharmaceutical composition is orally administered to the mammal.

25. The method of claim 21 wherein the pharmaceutical composition is parenterally administered to the mammal.

26. The method of claim 21 wherein the Src family tyrosine kinase inhibitor is a pyrazolopyrimidine class Src family tyrosine kinase inhibitor.

- 39 -

27. The method of claim 26 wherein the pyrazolopyrimidine class Src family tyrosine kinase inhibitor is selected from the group consisting of 4-amino-5-(4-methylphenyl)-7-(*t*-butyl)pyrazolo[3,4-*d*] pyrimidine, 4-amino-5-(4-chlorophenyl)-7-(*t*-butyl)pyrazolo[3,4-*d*] pyrimidine, and a mixture thereof.

28. The method of claim 21 wherein the Src family tyrosine kinase inhibitor is a 4-anilino-3-quinolinecarbonitrile compound.

29. The use of a chemical Src family tyrosine kinase inhibitor for the manufacture of a medicament for the treatment of myocardial infarction.

30. The use according to claim 29 wherein the chemical Src family tyrosine kinase inhibitor is selected from the group consisting of a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-*d*]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof.

31. The use according to claim 30 wherein the pyrazolopyrimidine class Src family tyrosine kinase inhibitor is selected from the group consisting of 4-amino-5-(4-methylphenyl)-7-(*t*-butyl)pyrazolo[3,4-*d*] pyrimidine, 4-amino-5-(4-chlorophenyl)-7-(*t*-butyl) pyrazolo[3,4-*d*]pyrimidine, and a mixture thereof.

32. The use according to claim 30 wherein the macrocyclic dienone class Src family tyrosine kinase inhibitor is selected from the group consisting of Geldanamycin, Herbimycin A, Radicicol R2146, and a mixture thereof.

33. The use according to claim 30 wherein the 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor is SKI-606.